Precision and Future Medicine最新文献_第7页

Proton therapy: the current status of the clinical evidences 质子治疗:临床证据的现状

IF 0.5

Precision and Future Medicine Pub Date : 2019-08-30 DOI: 10.23838/pfm.2019.00058

D. Oh

引用次数: 3

Sinus of Valsalva aneurysm after blunt chest trauma with complicated perforation by infective endocarditis 钝性胸部创伤并发感染性心内膜炎穿孔后瓦尔萨尔瓦动脉瘤窦

IF 0.5

Precision and Future Medicine Pub Date : 2019-06-30 DOI: 10.23838/PFM.2019.00030

C. Hyeon, Sung-Ji Park, So Ree Kim, Eun Kyoung Kim, S. Kim, Sung‐A Chang, Sang-Chol Lee, K. Sung, S. Park

引用次数: 1

Applications of diffusion-weighted imaging in diagnosis, evaluation, and treatment of acute ischemic stroke 弥散加权成像在急性缺血性脑卒中诊断、评价和治疗中的应用

IF 0.5

Precision and Future Medicine Pub Date : 2019-06-30 DOI: 10.23838/PFM.2019.00037

O. Bang, Wenyu Li

引用次数: 11

Analysis of microRNA expression in glial tumors by using a peptide nucleic acid-based microarray 利用基于肽核酸的微阵列分析胶质细胞肿瘤中微小RNA的表达

IF 0.5

Precision and Future Medicine Pub Date : 2019-06-04 DOI: 10.23838/PFM.2019.00044

Dae Cheol Kim, Young Zoon Kim

{"title":"Analysis of microRNA expression in glial tumors by using a peptide nucleic acid-based microarray","authors":"Dae Cheol Kim, Young Zoon Kim","doi":"10.23838/PFM.2019.00044","DOIUrl":"https://doi.org/10.23838/PFM.2019.00044","url":null,"abstract":"Purpose: Glial tumors are the most common primary brain tumors. However, their characteristics and prognosis are difficult to discern. There is currently an emphasis on microRNAs (miRNA) as candidate biomarkers for glial tumors. The aim of this study is to identify the specific miRNA patterns in glial tumors by using peptide nucleic acid (PNA)based microarrays in an assortment of glial tumors and normal tissue samples. Methods: Sample files were retrospectively assessed for cases diagnosed as glial tumors at the pathological archives of two institutes. miRNAs of 28 cases of glial tumors were analyzed by microarray. In order to verify the results, quantitative real-time polymerase chain reaction (RT-PCR) was performed. miRNA expression was calculated using the 2 method. The expression level of the miRNAs was compared using SPSS version 20.0 (IBM Co.). Results: miRNA expression profiling of glial tumors revealed that 62 miRNAs were detected from glioblastoma and benign brain tissue, with different expression patterns. The expression of miR-296-3p, miR-370, and miR-371-5p was shown to be involved in malignancy. These miRNAs were also increased in the glioblastoma with methylated O6-methyguanine DNA methyltransferase. The expression pattern of miR-296-3p shows same tendency in PNA-based microarray and RT-PCR. Conclusion: These analyses suggest that novel miRNAs can be applicable as diagnostic tools and target therapeutic agents, since miRNAs can positively or negatively regulate glioblastomas.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42282371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series 奥拉拉单抗和阿霉素治疗转移性软组织肉瘤:回顾性病例系列

IF 0.5

Precision and Future Medicine Pub Date : 2019-05-30 DOI: 10.23838/PFM.2019.00016

J. Hur, S. Park, Su Jin Lee

引用次数: 0

Bioreactor systems are essentially required for stem cell bioprocessing 干细胞生物处理基本上需要生物反应器系统

IF 0.5

Precision and Future Medicine Pub Date : 2019-03-31 DOI: 10.23838/PFM.2018.00128

J. Cha, Min-Young Lee, Jongin Hong

引用次数: 4

Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) BCR-ABL1 chimeric transcripts 分离单核细胞增多症是e1a2 (minor, P190) BCR-ABL1嵌合转录物慢性髓系白血病全血细胞计数其他参数异常的标志

IF 0.5

Precision and Future Medicine Pub Date : 2019-03-31 DOI: 10.23838/PFM.2019.00023

J. Yun, Jung Yoon, Jong-Won Kim, Sun-Hee Kim, C. Jung, Hee-Jin Kim

{"title":"Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) BCR-ABL1 chimeric transcripts","authors":"J. Yun, Jung Yoon, Jong-Won Kim, Sun-Hee Kim, C. Jung, Hee-Jin Kim","doi":"10.23838/PFM.2019.00023","DOIUrl":"https://doi.org/10.23838/PFM.2019.00023","url":null,"abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with the molecular hallmark of BCR-ABL1 chimeric transcripts from t(9;22)(q24;q22). In more than 95% of CML, the fusion occurs in the major breakpoint cluster region (M-bcr) of BCR, most commonly producing the e14a2 or e13a2 type. CML with e1a2 BCR-ABL1 by fusion in minor bcr is rare, accounting for approximately 1% of CML. CML with e1a2 BCR-ABL1 is reportedly associated with monocytosis and poor prognosis. Here we describe a woman who underwent bone marrow (BM) study with an impression of chronic myelomonocytic leukemia based on thrombocytosis and prominent monocytosis. Genetic workup revealed, however, t(9;22) and e1a2 BCR-ABL1, which indicated CML and explained her unusual monocytosis. A review of serial complete blood counts (CBC) before the BM study demonstrated that isolated monocytosis preceded the abnormalities in other parameters of CBC. The patient is on follow-up with tyrosine kinase inhibitor (TKI, dasatinib) medication. Close monitoring is required due to the association of e1a2 BCR-ABL1 with poor response to TKI and frequent disease progression. Timely genetic workup and determination of the precise type of BCR-ABL1 transcripts are critical for the diagnosis and stratification of this rare subtype of CML with distinct genotype-phenotype correlations.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45187717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Updates on Structural Neuroimaging of Narcolepsy with Cataplexy 发作性睡伴猝倒的结构神经影像学研究进展

IF 0.5

Precision and Future Medicine Pub Date : 2019-03-31 DOI: 10.23838/PFM.2018.00149

E. Joo

引用次数: 1

Chronic insomnia disorder: perspectives from structural neuroimaging 慢性失眠症:结构神经影像学的观点

IF 0.5

Precision and Future Medicine Pub Date : 2019-03-31 DOI: 10.23838/PFM.2018.00156

E. Joo

引用次数: 1

Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial 胃肿瘤辅助放化疗的安全性中期分析结果2试验：一项多中心、随机的III期临床试验

IF 0.5

Precision and Future Medicine Pub Date : 2019-03-13 DOI: 10.23838/PFM.2018.00177

S. Park, Jeeyun Lee, T. Sohn, D. Lim, Kyoung-Mee Kim, J. An, M. Choi, Jun Ho Lee, J. Bae, Sung Kim, Su Jin Lee, Seung-Tae Kim, Joon-Oh Park, Y. Park, Ho Yeong Lim, W. Kang

{"title":"Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial","authors":"S. Park, Jeeyun Lee, T. Sohn, D. Lim, Kyoung-Mee Kim, J. An, M. Choi, Jun Ho Lee, J. Bae, Sung Kim, Su Jin Lee, Seung-Tae Kim, Joon-Oh Park, Y. Park, Ho Yeong Lim, W. Kang","doi":"10.23838/PFM.2018.00177","DOIUrl":"https://doi.org/10.23838/PFM.2018.00177","url":null,"abstract":"Purpose: The Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) trial was conducted to compare the efficacy between adjuvant chemotherapy regimens and chemoradiotherapy in D2-resected, node-positive, stage 2 or 3 gastric cancer. Methods: In this prospective, multicenter, phase III trial, we randomly assigned patients to three treatment arms: patients who receive adjuvant S-1 for 1 year, S-1 plus oxaliplatin (SOX) for 6 months, or SOX plus chemoradiotherapy (SOXRT). Herein, we report the safety outcomes of patients who received adjuvant chemotherapy or chemoradiotherapy. Results: Among a total of 514 patients registered between February 2013 and December 2017, 499 patients who either completed or discontinued the assigned study treatments were included in the present analysis. All the three treatment arms were generally well-tolerated, with the overall treatment completion rate of 94% (96% in S-1, 93% in SOX, and 92% in SOXRT). The median delivered dose of radiotherapy in the SOXRT arm was 4,500 cGy (range, 0 to 4,500 cGy). The most frequently observed adverse events were fatigue (29%) in S-1 arm and peripheral neuropathy in the SOX and SOXRT arms (59% and 50%, respectively). Conclusion: Our preliminary data confirm that there are no significant safety concerns in ARTIST 2 trial (ClinicalTrials.gov, NCT0176146). According to the Independent Data Monitoring Committee, patient accrual is underway.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2019-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43227390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2